Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
fda save search
FDA Requires Boxed Warning for Secondary Cancers on CAR-T Therapies
Published: 2024-04-19 (Crawled : 12:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.83%
H: 1.35%
C: 1.2%
fda for car-t
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2024-04-18 (Crawled : 23:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
entyvio fda disease active for therapy
Patented AI Platform Identifies Promising Early-Stage BioPharma Assets and Co...
Published: 2024-04-18 (Crawled : 18:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: 0.0%
XOMA | News | $24.97 1.55% 1.52% 17K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
biopharma platform
Teva, Alvotech Secure FDA Approval for Stelara Biosimilar with Early 2025 Launch
Published: 2024-04-18 (Crawled : 14:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: 0.0%
fda biosimilar approval for stelara
Patented AI Platform Identifies Promising Early-Stage BioPharma Assets and Co...
Published: 2024-04-17 (Crawled : 14:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.28%
C: -0.16%
XOMA | News | $24.97 1.55% 1.52% 17K
|
Health Technology
|
| O: -1.48%
H: 1.08%
C: 0.96%
biopharma platform
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
Published: 2024-04-16 (Crawled : 21:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.28%
C: -0.16%
stelara fda biosimilar approval teva
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)
Published: 2024-04-16 (Crawled : 16:00) - biospace.com/
PTPI | $0.6849 -1.86% -1.9% 150K
|
|
| O: 9.85%
H: 4.63%
C: -18.04%
fda positive pharmaceuticals for technology response
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 26.26%
H: 73.2%
C: 18.87%
health cancer care for commercial
Patented AI Platform Identifies Promising Early-Stage BioPharma Assets and Co...
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -2.09%
H: 0.0%
C: 0.0%
XOMA | News | $24.97 1.55% 1.52% 17K
|
Health Technology
|
| O: 1.15%
H: 0.0%
C: -0.97%
biopharma platform
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
Published: 2024-04-16 (Crawled : 12:00) - globenewswire.com
BRTX | $1.39 -3.47% -3.6% 160K
|
Professional, Scientific, and T...
|
| O: 9.23%
H: 15.49%
C: -7.75%
brtx-100 fda clearance study
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
Published: 2024-04-16 (Crawled : 12:00) - globenewswire.com
LXEO | $11.995 -0.62% -0.63% 87K
|
|
| O: 5.32%
H: 0.0%
C: -2.63%
lx2006 fda candidate granted treatment designation for therapeutics therapy
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
MRZM | $0.095 1031.22% 2.2K
|
Information
|
| O: 0.0%
H: 72.73%
C: 72.73%
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: -4.91%
H: 3.23%
C: -3.29%
for commercialization therapeutics agreement
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
URGN | $13.78 -3.37% -3.48% 390K
|
Health Technology
|
| O: 1.46%
H: 1.17%
C: -1.44%
ugn-103 fda drug bladder cancer for application
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
SNGX | $0.4233 -2.76% -2.83% 1M
|
Health Technology
|
| O: 75.34%
H: 37.73%
C: -30.58%
fda drug marburg infection designation for grants
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
Published: 2024-04-15 (Crawled : 13:00) - globenewswire.com
RVPH | $3.035 0.5% 0.49% 140K
|
|
| O: -7.05%
H: 4.96%
C: 1.46%
fda brilaroxazine trials for schizophrenia
3D Systems Announces FDA Clearance for World’s First 3D-Printed PEEK Cranial Implants
Published: 2024-04-15 (Crawled : 13:00) - globenewswire.com
DDD F | $3.55 2.31% 0.0% 1.5M
|
Producer Manufacturing
|
| O: 5.95%
H: 0.26%
C: -9.95%
fda first clearance for
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
Published: 2024-04-15 (Crawled : 13:00) - globenewswire.com
RNAZ | $0.49 -2.39% -2.45% 110K
|
Professional, Scientific, and T...
|
| O: 0.11%
H: 5.95%
C: -13.78%
mc138 fda ttx-mc138 tumors clearance trial therapeutics advanced
Patented AI Platform Identifies Promising Early-Stage BioPharma Assets and Co...
Published: 2024-04-15 (Crawled : 06:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
XOMA | News | $24.97 1.55% 1.52% 17K
|
Health Technology
|
| O: -2.63%
H: 1.39%
C: -3.3%
biopharma platform
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
SNGX | $0.4233 -2.76% -2.83% 1M
|
Health Technology
|
| O: 3.67%
H: 0.46%
C: -19.02%
fda drug infection designation for grants
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
Published: 2024-04-11 (Crawled : 13:00) - globenewswire.com
CADL | $5.17 -5.31% -5.61% 520K
|
|
| O: 25.49%
H: 23.75%
C: 13.75%
can-2409 fda drug cancer pancreatic treatment designation for therapeutics
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.